-
1
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
2
-
-
0242694519
-
HER-2-targeted therapy: Lessons learned and future directions
-
Nahta R, Esteva F. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003;9:5078-84.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5078-5084
-
-
Nahta, R.1
Esteva, F.2
-
4
-
-
0344333420
-
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
-
Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-9.
-
(1998)
J Clin Oncol
, vol.16
, pp. 462-469
-
-
Sjogren, S.1
Inganas, M.2
Lindgren, A.3
Holmberg, L.4
Bergh, J.5
-
5
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
6
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
7
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
8
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
9
-
-
0036145181
-
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
-
Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
-
(2002)
J Pathol
, vol.196
, pp. 17-25
-
-
Suo, Z.1
Risberg, B.2
Kalsson, M.G.3
-
10
-
-
0034892806
-
Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers
-
Thor AD, Edgerton SM, Liu S, Moore DH II, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001;7:2415-24.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2415-2424
-
-
Thor, A.D.1
Edgerton, S.M.2
Liu, S.3
Moore II, D.H.4
Kwiatkowski, D.J.5
-
11
-
-
33746485766
-
Epidermal growth factor receptor targeting in cancer
-
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
-
(2006)
Semin Oncol
, vol.33
, pp. 369-385
-
-
Mendelsohn, J.1
Baselga, J.2
-
12
-
-
34250017061
-
Targeted agents in the treatment of pancreatic cancer: History and lessons learned
-
Bendell J, Goldberg RM. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr Opin Oncol 2007;19:390-5.
-
(2007)
Curr Opin Oncol
, vol.19
, pp. 390-395
-
-
Bendell, J.1
Goldberg, R.M.2
-
13
-
-
3042524076
-
-
Lynch TJ, Adjei AA, Bunn PA, Jr., et al. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004;10:4199-204s.
-
Lynch TJ, Adjei AA, Bunn PA, Jr., et al. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004;10:4199-204s.
-
-
-
-
14
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez J, Janne P, Lee J, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1458-61.
-
(2004)
Science
, vol.304
, pp. 1458-1461
-
-
Paez, J.1
Janne, P.2
Lee, J.3
-
15
-
-
2142708757
-
Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer
-
Arteaga C, Truica C. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 2004;31:3-8.
-
(2004)
Semin Oncol
, vol.31
, pp. 3-8
-
-
Arteaga, C.1
Truica, C.2
-
16
-
-
0036225446
-
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
-
Normanno N, Campiglio M, De Luca A, Somenzi G, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
-
(2002)
Ann Oncol
, vol.13
, pp. 65-72
-
-
Normanno, N.1
Campiglio, M.2
De Luca, A.3
Somenzi, G.4
-
17
-
-
1842478456
-
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): Drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
-
Warburton C, Dragowska WH, Gelmon K, et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004;10:2512-24.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2512-2524
-
-
Warburton, C.1
Dragowska, W.H.2
Gelmon, K.3
-
18
-
-
27144531039
-
Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer
-
Nakamura H, Takamori S, Fujii T, et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005;230:33-46.
-
(2005)
Cancer Lett
, vol.230
, pp. 33-46
-
-
Nakamura, H.1
Takamori, S.2
Fujii, T.3
-
19
-
-
22344457603
-
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy
-
Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11:5300-9.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5300-5309
-
-
Friess, T.1
Scheuer, W.2
Hasmann, M.3
-
21
-
-
18844471324
-
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
-
Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998;153:103-8.
-
(1998)
Am J Pathol
, vol.153
, pp. 103-108
-
-
Salven, P.1
Lymboussaki, A.2
Heikkila, P.3
-
22
-
-
0034925637
-
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells
-
Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001;12:129-35.
-
(2001)
Cell Growth Differ
, vol.12
, pp. 129-135
-
-
Price, D.J.1
Miralem, T.2
Jiang, S.3
Steinberg, R.4
Avraham, H.5
-
23
-
-
0035422178
-
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells
-
Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40.
-
(2001)
Cancer Res
, vol.61
, pp. 5736-5740
-
-
Bachelder, R.E.1
Crago, A.2
Chung, J.3
-
24
-
-
0032713067
-
Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat
-
Xie B, Tam NN, Tsao SW, Wong YC. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br J Cancer 1999;81:1335-43.
-
(1999)
Br J Cancer
, vol.81
, pp. 1335-1343
-
-
Xie, B.1
Tam, N.N.2
Tsao, S.W.3
Wong, Y.C.4
-
25
-
-
0033032991
-
Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer
-
Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999;84:293-8.
-
(1999)
Int J Cancer
, vol.84
, pp. 293-298
-
-
Kranz, A.1
Mattfeldt, T.2
Waltenberger, J.3
-
26
-
-
0034000338
-
Prognostic value of vascular endothelial growth factor in breast cancer
-
Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5 Suppl 1:37-44.
-
(2000)
Oncologist
, vol.5
, Issue.SUPPL. 1
, pp. 37-44
-
-
Gasparini, G.1
-
27
-
-
0027197245
-
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
-
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
-
(1993)
Nature
, vol.362
, pp. 841-844
-
-
Kim, K.J.1
Li, B.2
Winer, J.3
-
28
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
30
-
-
0035885932
-
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
-
Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-13.
-
(2001)
Blood
, vol.98
, pp. 1904-1913
-
-
Masood, R.1
Cai, J.2
Zheng, T.3
Smith, D.L.4
Hinton, D.R.5
Gill, P.S.6
-
31
-
-
28744454292
-
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro
-
Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005;8:197-204.
-
(2005)
Angiogenesis
, vol.8
, pp. 197-204
-
-
Weigand, M.1
Hantel, P.2
Kreienberg, R.3
Waltenberger, J.4
-
32
-
-
17444388550
-
A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells
-
Akahane M, Akahane T, Shah A, Okajima E, Thorgeirsson UP. A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res 2005;25:701-7.
-
(2005)
Anticancer Res
, vol.25
, pp. 701-707
-
-
Akahane, M.1
Akahane, T.2
Shah, A.3
Okajima, E.4
Thorgeirsson, U.P.5
-
33
-
-
0037458645
-
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β1. A critical role of p38/nuclear factor-κB signaling pathway
-
Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β1. A critical role of p38/nuclear factor-κB signaling pathway. J Biol Chem 2003;278:5750-9.
-
(2003)
J Biol Chem
, vol.278
, pp. 5750-5759
-
-
Tsai, P.W.1
Shiah, S.G.2
Lin, M.T.3
Wu, C.W.4
Kuo, M.L.5
-
34
-
-
0034691674
-
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
-
Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-9.
-
(2000)
Oncogene
, vol.19
, pp. 3460-3469
-
-
Yen, L.1
You, X.L.2
Al Moustafa, A.E.3
-
35
-
-
0036604183
-
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma
-
Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002;94:2855-61.
-
(2002)
Cancer
, vol.94
, pp. 2855-2861
-
-
Yang, W.1
Klos, K.2
Yang, Y.3
Smith, T.L.4
Shi, D.5
Yu, D.6
-
36
-
-
0346366639
-
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment
-
Linderholm B, Andersson J, Lindh B, et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 2004;40:33-42.
-
(2004)
Eur J Cancer
, vol.40
, pp. 33-42
-
-
Linderholm, B.1
Andersson, J.2
Lindh, B.3
-
37
-
-
0027412319
-
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
-
Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33.
-
(1993)
Mol Biol Cell
, vol.4
, pp. 121-133
-
-
Goldman, C.K.1
Kim, J.2
Wong, W.L.3
King, V.4
Brock, T.5
Gillespie, G.Y.6
-
38
-
-
33645499486
-
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms
-
Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006;66:3197-204.
-
(2006)
Cancer Res
, vol.66
, pp. 3197-3204
-
-
Pore, N.1
Jiang, Z.2
Gupta, A.3
Cerniglia, G.4
Kao, G.D.5
Maity, A.6
-
39
-
-
0034667464
-
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia
-
Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.
-
(2000)
Cancer Res
, vol.60
, pp. 5879-5886
-
-
Maity, A.1
Pore, N.2
Lee, J.3
Solomon, D.4
O'Rourke, D.M.5
-
40
-
-
0001223491
-
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
-
Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
-
(1997)
Am J Pathol
, vol.151
, pp. 1523-1530
-
-
Petit, A.M.1
Rak, J.2
Hung, M.C.3
-
41
-
-
0034896362
-
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
-
Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1459-1465
-
-
Ciardiello, F.1
Caputo, R.2
Bianco, R.3
-
42
-
-
33646133900
-
HER2 expression as a potential marker for response to therapy targeted to the EGFR
-
Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE. HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 2006;94:1144-53.
-
(2006)
Br J Cancer
, vol.94
, pp. 1144-1153
-
-
Emlet, D.R.1
Schwartz, R.2
Brown, K.A.3
Pollice, A.A.4
Smith, C.A.5
Shackney, S.E.6
-
43
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
44
-
-
5144223438
-
Phase I trial of irinotecan, infusional 5fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities
-
Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004;10:6522-7.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6522-6527
-
-
Messersmith, W.A.1
Laheru, D.A.2
Senzer, N.N.3
-
45
-
-
33846263629
-
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
-
Patnaik A, Wood D, Tolcher AW, et al. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006;12:7406-13.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7406-7413
-
-
Patnaik, A.1
Wood, D.2
Tolcher, A.W.3
-
46
-
-
0037388251
-
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
-
Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-83.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1274-1283
-
-
Anido, J.1
Matar, P.2
Albanell, J.3
-
47
-
-
33747402650
-
Two targets, one drug for new EGFR inhibitors
-
McNeil C. Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 2006;98:1102-3.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 1102-1103
-
-
McNeil, C.1
-
48
-
-
0034076307
-
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
-
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
|